HC Wainwright Analysts Decrease Earnings Estimates for HURA

TuHURA Biosciences, Inc. (NASDAQ:HURA) – Research analysts at HC Wainwright reduced their FY2025 earnings per share estimates for shares of TuHURA Biosciences in a report issued on Monday, June 30th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($0.57) per share for the year, down from their prior forecast of ($0.56). HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. HC Wainwright also issued estimates for TuHURA Biosciences’ Q4 2025 earnings at ($0.14) EPS and FY2026 earnings at ($0.53) EPS.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02).

Other equities analysts have also recently issued research reports about the company. Brookline Capital Management upgraded TuHURA Biosciences to a “strong-buy” rating in a report on Monday, June 23rd. Wall Street Zen downgraded shares of TuHURA Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, June 14th. One analyst has rated the stock with a sell rating, three have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $12.67.

TuHURA Biosciences Stock Down 5.4%

Shares of TuHURA Biosciences stock opened at $2.47 on Wednesday. The stock’s fifty day simple moving average is $3.13 and its 200 day simple moving average is $3.59. TuHURA Biosciences has a 12 month low of $1.80 and a 12 month high of $7.93.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of HURA. Geode Capital Management LLC bought a new stake in TuHURA Biosciences in the 4th quarter valued at approximately $1,084,000. Apollon Wealth Management LLC raised its holdings in shares of TuHURA Biosciences by 86.0% in the first quarter. Apollon Wealth Management LLC now owns 114,926 shares of the company’s stock valued at $371,000 after purchasing an additional 53,154 shares during the last quarter. Northern Trust Corp acquired a new stake in shares of TuHURA Biosciences in the fourth quarter valued at approximately $234,000. Squarepoint Ops LLC bought a new stake in shares of TuHURA Biosciences in the fourth quarter worth $223,000. Finally, Hurlow Wealth Management Group Inc. acquired a new position in TuHURA Biosciences during the fourth quarter worth $170,000. 0.62% of the stock is owned by institutional investors and hedge funds.

About TuHURA Biosciences

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.